SCHEMBL13307461

SCHEMBL13307461

CC(=O)c1cc(N)cc(C(=O)N(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.40
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 3/20 0.37
FURIN P09958 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CREBBP Q92793 1/20 0.35
LMNA P02545 1/20 0.34
PRKCI P41743 1/20 0.34
KIF11 P52732 2/20 0.33
MAOB P27338 1/20 0.33
AOC3 Q16853 1/20 0.33
ERN1 O75460 1/20 0.33
HSP90AA1 P07900 1/20 0.32
PDK2 Q15119 1/20 0.32
MAP4K1 Q92918 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583560 0.92 ALDH1A1 (0.43) ALDH1A1HPGDSMN1; SMN2MAPTFURIN
SCHEMBL13307454 0.89 CA5A (0.48) CA5AALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL13307453 0.89 CA5A (0.48) CA5AALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL24041391 0.87 ALDH1A1 (0.43) ALDH1A1HPGDSMN1; SMN2MAPTKDM4E
SCHEMBL1976289 0.85 CA5A (0.52) CA5AALDH1A1HPGDMAPTFURIN
SCHEMBL13307467 0.84 CA5A (0.40) CA5AALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL12852900 0.84 SMN1; SMN2 (0.38) ALDH1A1HPGDSMN1; SMN2MAPTFURIN
SCHEMBL13307452 0.82 TPMT (0.41) CA5AALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL13307464 0.82 TPMT (0.41) CA5AALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL2628599 0.80 CA5A (0.52) CA5AALDH1A1HPGDMAPTFURIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CA5A 2861/4885ALDH1A1 2133/4885HPGD 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.